Spooner K, et al. - In patients with persistent macular oedema secondary to retinal vein occlusions (RVO), investigators systematically reviewed anatomical and functional outcomes of switching therapy from bevacizumab and/or ranibizumab to aflibercept. A systematic search for aflibercept was carried out in EMBASE, PubMed and Cochrane databases prior to June 2017 for the treatment of persistent macular oedema secondary to the branch and central RVO. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were the main outcome variables described. After switching to aflibercept at 6 months but not 12 months, significant improvements in mean CMT were observed. Persistent macular oedema secondary to RVO might be improved by switching from bevacizumab/ranibizumab to aflibercept. However, the potential for visual recovery might be limited.